Physician profile
Kylee Sacksteder
NPI 1871918375
$12,710.39
in general payments reported to CMS, 2019-2025
37 companies · $2,910 in 2025
The $2,910 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,100 · 2020: $722 · 2021: $1,419 · 2022: $1,569 · 2023: $1,812 · 2024: $2,178 · 2025: $2,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,649 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,649.31 |
| Education | $250.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,372.66 | 2019-2025 | Tremfya |
| Genzyme Corporation | $1,304.94 | 2019-2025 | |
| Abbvie INC. | $1,279.91 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $1,262.03 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,046.89 | 2019-2025 | Ilumya, Winlevi |
| Novartis Pharmaceuticals Corporation | $690.95 | 2019-2025 | |
| Biofrontera INC. | $661.49 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Leo Pharma INC. | $629.41 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $611.99 | 2022-2025 | Sotyktu |
| Amgen INC. | $545.81 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $462.82 | 2020-2025 | Nemluvio, Twyneo, Aklief |
| Regeneron Healthcare Solutions, INC. | $409.97 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $357.40 | 2023-2024 | Vtama |
| Pfizer INC. | $342.91 | 2019-2025 | |
| Hill Dermaceuticals, INC. | $247.24 | 2024 | Tolak |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $230.25 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $223.62 | 2023-2025 | Zoryve |
| Incyte Corporation | $171.00 | 2022-2025 | Opzelura |
| Ucb, INC. | $143.23 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.41 | 2021-2024 | Arazlo, Cabtreo, Jublia |
| Organon LLC | $90.17 | 2025 | Vtama |
| Dusa Pharmaceuticals, INC. | $63.42 | 2019 | |
| Celgene Corporation | $58.56 | 2019 | |
| Almirall LLC | $50.78 | 2019-2025 | Klisyri |
| Dermira, INC. | $47.61 | 2019-2020 | |
| Epi Health, LLC | $44.08 | 2019-2021 | |
| Botanix Sb INC | $42.20 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $35.89 | 2021 | |
| Organogenesis INC. | $31.62 | 2024 | |
| Cipher Pharmaceuticals US LLC | $28.24 | 2025 | Spinosad, Natroba |
| Mayne Pharma Commercial LLC | $26.07 | 2022-2025 | |
| Tempus Ai, INC | $22.36 | 2024 | |
| Janssen Scientific Affairs, LLC | $22.35 | 2021 | |
| Lnhc, INC | $19.88 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $13.97 | 2023 | Ycanth |
| Sandoz INC. | $13.78 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylee Sacksteder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.